• LAST PRICE
    5.3200
  • TODAY'S CHANGE (%)
    Trending Up0.3200 (6.4000%)
  • Bid / Lots
    5.2600/ 3
  • Ask / Lots
    5.3200/ 2
  • Open / Previous Close
    4.8245 / 5.0000
  • Day Range
    Low 4.8245
    High 5.3200
  • 52 Week Range
    Low 1.5300
    High 9.2200
  • Volume
    32,787
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5
TimeVolumeLRMR
09:32 ET16504.894
09:37 ET34474.96
09:48 ET1004.95
10:02 ET2004.9435
10:13 ET5004.9599
10:20 ET27325.07
10:40 ET10005.15
10:51 ET35765.18
10:58 ET7005.175
11:02 ET4005.19
11:03 ET1005.21
11:12 ET18005.22
11:20 ET1005.25
11:21 ET6005.2499
11:23 ET135535.3
11:25 ET1005.32
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLRMR
Larimar Therapeutics Inc
216.3M
-2.9x
---
United StatesTNYA
Tenaya Therapeutics Inc
207.3M
-1.1x
---
United StatesPRAX
Praxis Precision Medicines Inc
225.7M
-0.9x
---
United StatesCYDY
Cytodyn Inc
225.9M
-1.0x
---
United StatesACIU
AC Immune SA
207.2M
-2.6x
---
United StatesOMIC
Singular Genomics Systems Inc
204.2M
-2.3x
---
As of 2023-02-03

Company Information

Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.

Contact Information

Headquarters
THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
Phone
617-622-4003
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joseph Truitt
President, Chief Executive Officer, Director
Carole Ben-Maimon
Chief Financial Officer, Company Secretary
Michael Celano
Independent Director
Peter Barrett
Independent Director
Thomas Hamilton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$216.3M
Revenue (TTM)
$0.00
Shares Outstanding
43.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.55
EPS
$-1.83
Book Value
$3.64
P/E Ratio
-2.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.